MLICM
TVRD

Metropolitan Life Insurance Company (MetLife)’s Tvardi Therapeutics TVRD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69
Closed -$7.05K – 2457
2023
Q2 		$7.05K Buy
69
+34
+97% +$4.68K ﹤0.01% 2427
2023
Q1 		$6.24K Sell
35
-48
-58% -$16.1K ﹤0.01% 2261
2022
Q4 		$32.1K Hold
83
– – ﹤0.01% 1753
2022
Q3 		$28K Hold
83
– – ﹤0.01% 1833
2022
Q2 		$27.3K Hold
83
– – ﹤0.01% 1884
2022
Q1 		$36.3K Sell
83
-254
-75% -$104K ﹤0.01% 1770
2021
Q4 		$148K Sell
337
-33
-9% -$16.6K ﹤0.01% 2230
2021
Q3 		$206K Hold
370
– – ﹤0.01% 2049
2021
Q2 		$190K Buy
370
+13
+4% +$8.24K ﹤0.01% 2180
2021
Q1 		$279K Hold
357
– – ﹤0.01% 1791
2020
Q4 		$194K Hold
357
– – ﹤0.01% 1958
2020
Q3 		$163K Hold
357
– – ﹤0.01% 1910
2020
Q2 		$220K Hold
357
– – ﹤0.01% 1734
2020
Q1 		$170K Buy
357
+14
+4% +$7.61K ﹤0.01% 1684
2019
Q4 		$199K Sell
343
-24
-7% -$16.8K ﹤0.01% 1935
2019
Q3 		$242K Buy
367
+51
+16% +$42.4K ﹤0.01% 1746
2019
Q2 		$245K Hold
316
– – ﹤0.01% 1762
2019
Q1 		$223K Hold
316
– – ﹤0.01% 1832
2018
Q4 		$148K Buy
+316
New +$204K ﹤0.01% 2016
2018
Q3 		– Sell
-241
Closed -$166K – 2628
2018
Q2 		$166K Hold
241
– – ﹤0.01% 2055
2018
Q1 		$108K Hold
241
– – ﹤0.01% 2254
2017
Q4 		$106K Sell
241
-219
-48% -$99.8K ﹤0.01% 2280
2017
Q3 		$227K Hold
460
– – ﹤0.01% 2208
2017
Q2 		$255K Hold
460
– – ﹤0.01% 2183
2017
Q1 		$305K Buy
+460
New +$246K ﹤0.01% 1989
2016
Q1 		– Sell
-371
Closed -$225K – 2526
2015
Q4 		$225K Buy
371
+25
+7% +$13.7K ﹤0.01% 2175
2015
Q3 		$178K Buy
+346
New +$232K ﹤0.01% 2363

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TVRD Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 69 shares — an estimated $7.05K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TVRD in Q3 2015 and held it in 27 quarters. The position peaked at $305K in Q1 2017. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 69 Tvardi Therapeutics shares in Q3 2023, an estimated $7.05K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 27 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Tvardi Therapeutics position peaked at $305K in Q1 2017.
  • 122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.